The efficacy of oral deferiprone in acute iron poisoning
| Autor: | Julia Klein, Gideon Koren, Michael Segal, Clara Talmor, G Lushkov, Matitiahu Berkovitch, Amir Livne, Yedidia Bentur |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Male
medicine.medical_specialty Time Factors Pyridones medicine.medical_treatment Thalassemia Iron Drug Evaluation Preclinical Administration Oral Biological Availability Iron Chelating Agents Gastroenterology Iron poisoning Lethal Dose 50 chemistry.chemical_compound Route of administration Pharmacokinetics Oral administration Internal medicine medicine Animals Deferiprone Tissue Distribution Rats Wistar Chemotherapy business.industry Poisoning General Medicine medicine.disease Survival Analysis Rats Deferoxamine Disease Models Animal chemistry Anesthesia Acute Disease Emergency Medicine Morbidity business medicine.drug |
| Zdroj: | The American journal of emergency medicine. 18(1) |
| ISSN: | 0735-6757 |
| Popis: | Due to its high cost and need for parenteral administration, the standard iron chelator deferoxamine is not used in many individuals with acute and chronic iron poisoning worldwide. Deferiprone is the first oral iron chelator to be shown to be effective in chronically iron overloaded thalassemia patients. Its efficacy, by oral administration, in acute iron poisoning has not been tested. Our objective was to determine whether orally administered deferiprone can reduce the mortality of rats following acute, toxic, oral doses of iron. Rats were administered 612 mg/kg elemental iron orally, corresponding to LD50 in the species tested. Two other groups received the same oral dose of iron followed by oral deferiprone: 800 mg/kg and 800 mg/kg, followed by another dose of 800 mg/kg 2 hours later. Coadministration of 800 mg/kg deferiprone with the iron decreased mortality from 30% to 6.6% after 2 hours (P = .02), from 40% to 16.6% after 12 hours (P = .04), and from 53.3% to 20% after 24 hours (P = 0.007). Mortality was also significantly decreased among animals coadministrated 2 repeated doses of deferiprone of 800 mg/kg with iron, to 0%, 9%, and 18%, and 2, 12, and 24 hours postdrug administration, respectively (P = .04, .05, .04, respectively). Histologically, there was a dose-dependent decrease in iron accumulation in the gastrointestinal tract. Orally administered deferiprone can decrease morbidity and mortality caused by acute iron overdose in rats. Oral deferiprone holds promise in the treatment of iron poisoning in humans. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect